Defects of Innate Immunity

  • Jana P. Lovell
  • Steven M. HollandEmail author


White blood cells (WBCs) encompass a diversity of cells, which can be classified into two broad categories: lymphoid (T, B, NK, and NKT) and myeloid (neutrophils, eosinophils, basophils, and monocytes/macrophages, as well as those derived from the same progenitors, erythroid, and megakaryocytic). This chapter focuses primarily on neutrophils and monocytes and examines the disorders characterized by their quantitative and functional defects.


  1. 1.
    Celkan T, Koc BS. Approach to the patient with neutropenia in childhood. Turk Pediatri Arsivi. 2015;50:136–44. Scholar
  2. 2.
    Dong F, et al. Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia. N Engl J Med. 1995;333:487–93. Scholar
  3. 3.
    Germeshausen M, Skokowa J, Ballmaier M, Zeidler C, Welte K. G-CSF receptor mutations in patients with congenital neutropenia. Curr Opin Hematol. 2008;15:332–7. Scholar
  4. 4.
    Dale DC, et al. Severe chronic neutropenia: treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry. Am J Hematol. 2003;72:82–93. Scholar
  5. 5.
    Connelly JA, Choi SW, Levine JE. Hematopoietic stem cell transplantation for severe congenital neutropenia. Curr Opin Hematol. 2012;19:44–51. Scholar
  6. 6.
    Kostmann R. Infantile genetic agranulocytosis; agranulocytosis infantilis hereditaria. Acta Paediatr Suppl. 1956;45:1–78.CrossRefPubMedGoogle Scholar
  7. 7.
    Klein C, et al. HAX1 deficiency causes autosomal recessive severe congenital neutropenia (Kostmann disease). Nat Genet. 2007;39:86–92. Scholar
  8. 8.
    Germeshausen M, et al. Novel HAX1 mutations in patients with severe congenital neutropenia reveal isoform-dependent genotype-phenotype associations. Blood. 2008;111:4954–7. Scholar
  9. 9.
    Roques G, et al. Neurological findings and genetic alterations in patients with Kostmann syndrome and HAX1 mutations. Pediatr Blood Cancer. 2014;61:1041–8. Scholar
  10. 10.
    Pannicke U, et al. Reticular dysgenesis (aleukocytosis) is caused by mutations in the gene encoding mitochondrial adenylate kinase 2. Nat Genet. 2009;41:101–5. Scholar
  11. 11.
    Lagresle-Peyrou C, et al. Human adenylate kinase 2 deficiency causes a profound hematopoietic defect associated with sensorineural deafness. Nat Genet. 2009;41:106–11. Scholar
  12. 12.
    Six E, et al. AK2 deficiency compromises the mitochondrial energy metabolism required for differentiation of human neutrophil and lymphoid lineages. Cell Death Dis. 2015;6:e1856. Scholar
  13. 13.
    Al-Zahrani D, Al-Ghonaium A, Al-Mousa H, Al-Kassar A, Roifman CM. Skeletal abnormalities and successful hematopoietic stem cell transplantation in patients with reticular dysgenesis. J Allergy Clin Immunol. 2013;132:993–6. Scholar
  14. 14.
    Boztug K, et al. A syndrome with congenital neutropenia and mutations in G6PC3. N Engl J Med. 2009;360:32–43. Scholar
  15. 15.
    Banka S. GeneReviews is a registered trademark of the University of Washington, Seattle. In: Pagon, RA, et al., editors. GeneReviews(R). University of Washington, Seattle, University of Washington, Seattle. All rights reserved; 1993.Google Scholar
  16. 16.
    Jun HS, et al. Lack of glucose recycling between endoplasmic reticulum and cytoplasm underlies cellular dysfunction in glucose-6-phosphatase-beta-deficient neutrophils in a congenital neutropenia syndrome. Blood. 2010;116:2783–92. Scholar
  17. 17.
    Jun HS, Cheung YY, Lee YM, Mansfield BC, Chou JY. Glucose-6-phosphatase-beta, implicated in a congenital neutropenia syndrome, is essential for macrophage energy homeostasis and functionality. Blood. 2012;119:4047–55. Scholar
  18. 18.
    Horwitz MS, et al. Neutrophil elastase in cyclic and severe congenital neutropenia. Blood. 2007;109:1817–24. Scholar
  19. 19.
    Dale DC, et al. Mutations in the gene encoding neutrophil elastase in congenital and cyclic neutropenia. Blood. 2000;96:2317–22.PubMedGoogle Scholar
  20. 20.
    Horwitz MS, Corey SJ, Grimes HL, Tidwell T. ELANE mutations in cyclic and severe congenital neutropenia: genetics and pathophysiology. Hematol Oncol Clin North Am. 2013;27:19–41., vii. Scholar
  21. 21.
    Person RE, et al. Mutations in proto-oncogene GFI1 cause human neutropenia and target ELA2. Nat Genet. 2003;34:308–12. Scholar
  22. 22.
    Zarebski A, et al. Mutations in growth factor independent-1 associated with human neutropenia block murine granulopoiesis through colony stimulating factor-1. Immunity. 2008;28:370–80. Scholar
  23. 23.
    Devriendt K, et al. Constitutively activating mutation in WASP causes X-linked severe congenital neutropenia. Nat Genet. 2001;27:313–7. Scholar
  24. 24.
    Ancliff PJ, et al. Two novel activating mutations in the Wiskott-Aldrich syndrome protein result in congenital neutropenia. Blood. 2006;108:2182–9. Scholar
  25. 25.
    Makaryan V, et al. The diversity of mutations and clinical outcomes for ELANE-associated neutropenia. Curr Opin Hematol. 2015;22:3–11. Scholar
  26. 26.
    Palmer SE, Stephens K, Dale DC. Genetics, phenotype, and natural history of autosomal dominant cyclic hematopoiesis. Am J Med Genet. 1996;66:413–22.<413::aid-ajmg5>;2-l.CrossRefPubMedGoogle Scholar
  27. 27.
    Wright DG, Dale DC, Fauci AS, Wolff SM. Human cyclic neutropenia: clinical review and long-term follow-up of patients. Medicine (Baltimore). 1981;60:1–13.CrossRefGoogle Scholar
  28. 28.
    Dale DC, Hammond WPT. Cyclic neutropenia: a clinical review. Blood Rev. 1988;2:178–85.CrossRefPubMedGoogle Scholar
  29. 29.
    Souid AK. Congenital cyclic neutropenia. Clin Pediatr. 1995;34:151–5.CrossRefGoogle Scholar
  30. 30.
    Rose MG, Berliner N. T-cell large granular lymphocyte leukemia and related disorders. Oncologist. 2004;9:247–58.CrossRefPubMedGoogle Scholar
  31. 31.
    Loughran TP Jr, Clark EA, Price TH, Hammond WP. Adult-onset cyclic neutropenia is associated with increased large granular lymphocytes. Blood. 1986;68:1082–7.PubMedGoogle Scholar
  32. 32.
    Hernandez PA, et al. Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease. Nat Genet. 2003;34:70–4. Scholar
  33. 33.
    Balabanian K, et al. WHIM syndromes with different genetic anomalies are accounted for by impaired CXCR4 desensitization to CXCL12. Blood. 2005;105:2449–57. Scholar
  34. 34.
    Balabanian K, et al. Leukocyte analysis from WHIM syndrome patients reveals a pivotal role for GRK3 in CXCR4 signaling. J Clin Invest. 2008;118:1074–84. Scholar
  35. 35.
    Al Ustwani O, Kurzrock R, Wetzler M. Genetics on a WHIM. Br J Haematol. 2014;164:15–23. Scholar
  36. 36.
    McDermott DH, et al. A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor. Blood. 2014;123:2308–16. Scholar
  37. 37.
    Dale DC, et al. The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis WHIM syndrome. Blood. 2011;118:4963–6. Scholar
  38. 38.
    Dale DC. Immune and idiopathic neutropenia. Curr Opin Hematol. 1998;5:33–6.CrossRefPubMedGoogle Scholar
  39. 39.
    Huizinga TW, et al. Maternal genomic neutrophil FcRIII deficiency leading to neonatal isoimmune neutropenia. Blood. 1990;76:1927–32.PubMedGoogle Scholar
  40. 40.
    Stroncek DF, et al. Alloimmune neonatal neutropenia due to an antibody to the neutrophil Fc-gamma receptor III with maternal deficiency of CD16 antigen. Blood. 1991;77:1572–80.PubMedGoogle Scholar
  41. 41.
    Fromont P, et al. Frequency of the polymorphonuclear neutrophil Fc gamma receptor III deficiency in the French population and its involvement in the development of neonatal alloimmune neutropenia. Blood. 1992;79:2131–4.PubMedGoogle Scholar
  42. 42.
    Maheshwari A, Christensen RD, Calhoun DA. Immune-mediated neutropenia in the neonate. Acta Paediatr Suppl. 2002;91:98–103.CrossRefPubMedGoogle Scholar
  43. 43.
    Akhtari M, Curtis B, Waller EK. Autoimmune neutropenia in adults. Autoimmun Rev. 2009;9:62–6. Scholar
  44. 44.
    Farruggia P. Immune neutropenias of infancy and childhood. World J Pediatr: WJP. 2016;12:142–8. Scholar
  45. 45.
    Barbosa MD, et al. Identification of the homologous beige and Chediak-Higashi syndrome genes. Nature. 1996;382:262–5. Scholar
  46. 46.
    Nagle DL, et al. Identification and mutation analysis of the complete gene for Chediak-Higashi syndrome. Nat Genet. 1996;14:307–11. Scholar
  47. 47.
    Eapen M, et al. Hematopoietic cell transplantation for Chediak-Higashi syndrome. Bone Marrow Transplant. 2007;39:411–5. Scholar
  48. 48.
    Gallin JI, et al. Human neutrophil-specific granule deficiency: a model to assess the role of neutrophil-specific granules in the evolution of the inflammatory response. Blood. 1982;59:1317–29.PubMedGoogle Scholar
  49. 49.
    Lekstrom-Himes JA, Dorman SE, Kopar P, Holland SM, Gallin JI. Neutrophil-specific granule deficiency results from a novel mutation with loss of function of the transcription factor CCAAT/enhancer binding protein epsilon. J Exp Med. 1999;189:1847–52.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Lekstrom-Himes J, Xanthopoulos KG. Biological role of the CCAAT/enhancer-binding protein family of transcription factors. J Biol Chem. 1998;273:28545–8.CrossRefPubMedGoogle Scholar
  51. 51.
    Gombart AF, Koeffler HP. Neutrophil specific granule deficiency and mutations in the gene encoding transcription factor C/EBP(epsilon). Curr Opin Hematol. 2002;9:36–42.CrossRefPubMedGoogle Scholar
  52. 52.
    Wynn RF, et al. Intractable diarrhoea of infancy caused by neutrophil specific granule deficiency and cured by stem cell transplantation. Gut. 2006;55:292–3. Scholar
  53. 53.
    Segal BH, Leto TL, Gallin JI, Malech HL, Holland SM. Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine (Baltimore). 2000;79:170–200.CrossRefGoogle Scholar
  54. 54.
    Reeves EP, et al. Killing activity of neutrophils is mediated through activation of proteases by K+ flux. Nature. 2002;416:291–7. Scholar
  55. 55.
    Winkelstein JA, et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore). 2000;79:155–69.CrossRefGoogle Scholar
  56. 56.
    Lublin M, et al. Hepatic abscess in patients with chronic granulomatous disease. Ann Surg. 2002;235:383–91.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Leiding JW, et al. Corticosteroid therapy for liver abscess in chronic granulomatous disease. Clin Infect Dis. 2012;54:694–700. Scholar
  58. 58.
    Marciano BE, et al. Gastrointestinal involvement in chronic granulomatous disease. Pediatrics. 2004;114:462–8.CrossRefPubMedGoogle Scholar
  59. 59.
    Uzel G, et al. Complications of tumor necrosis factor-alpha blockade in chronic granulomatous disease-related colitis. Clin Infect Dis. 2010;51:1429–34. Scholar
  60. 60.
    Walther MM, et al. The urological manifestations of chronic granulomatous disease. J Urol. 1992;147:1314–8.CrossRefPubMedGoogle Scholar
  61. 61.
    Chin TW, Stiehm ER, Falloon J, Gallin JI. Corticosteroids in treatment of obstructive lesions of chronic granulomatous disease. J Pediatr. 1987;111:349–52.CrossRefPubMedGoogle Scholar
  62. 62.
    Quie PG, Belani KK. Corticosteroids for chronic granulomatous disease. J Pediatr. 1987;111:393–4.CrossRefPubMedGoogle Scholar
  63. 63.
    Goldblatt D, Butcher J, Thrasher AJ, Russell-Eggitt I. Chorioretinal lesions in patients and carriers of chronic granulomatous disease. J Pediatr. 1999;134:780–3.CrossRefPubMedGoogle Scholar
  64. 64.
    Kim SJ, Kim JG, Yu YS. Chorioretinal lesions in patients with chronic granulomatous disease. Retina (Philadelphia, Pa). 2003;23:360–5.CrossRefGoogle Scholar
  65. 65.
    Manzi S, et al. Systemic lupus erythematosus in a boy with chronic granulomatous disease: case report and review of the literature. Arthritis Rheum. 1991;34:101–5.CrossRefPubMedGoogle Scholar
  66. 66.
    Cale CM, Morton L, Goldblatt D. Cutaneous and other lupus-like symptoms in carriers of X-linked chronic granulomatous disease: incidence and autoimmune serology. Clin Exp Immunol. 2007;148:79–84. Scholar
  67. 67.
    Vowells SJ, et al. Genotype-dependent variability in flow cytometric evaluation of reduced nicotinamide adenine dinucleotide phosphate oxidase function in patients with chronic granulomatous disease. J Pediatr. 1996;128:104–7.CrossRefPubMedGoogle Scholar
  68. 68.
    Vowells SJ, Sekhsaria S, Malech HL, Shalit M, Fleisher TA. Flow cytometric analysis of the granulocyte respiratory burst: a comparison study of fluorescent probes. J Immunol Methods. 1995;178:89–97.CrossRefPubMedGoogle Scholar
  69. 69.
    Nauseef WM. Myeloperoxidase deficiency. Hematol Oncol Clin North Am. 1988;2:135–58.CrossRefPubMedGoogle Scholar
  70. 70.
    Okuda T, Yasuoka T, Oka N. Myeloperoxidase deficiency as a predisposing factor for deep mucocutaneous candidiasis: a case report. J Oral Maxillofac Surg (Official Journal of the American Association of Oral and Maxillofacial Surgeons). 1991;49:183–6.CrossRefGoogle Scholar
  71. 71.
    Ludviksson BR, Thorarensen O, Gudnason T, Halldorsson S. Candida albicans meningitis in a child with myeloperoxidase deficiency. Pediatr Infect Dis J. 1993;12:162–4.CrossRefPubMedGoogle Scholar
  72. 72.
    Nguyen C, Katner HP. Myeloperoxidase deficiency manifesting as pustular candidal dermatitis. Clin Infect Dis. 1997;24:258–60.CrossRefPubMedGoogle Scholar
  73. 73.
    Chiang AK, et al. Disseminated fungal infection associated with myeloperoxidase deficiency in a premature neonate. Pediatr Infect Dis J. 2000;19:1027–9.CrossRefPubMedGoogle Scholar
  74. 74.
    Notarangelo LD, Badolato R. Leukocyte trafficking in primary immunodeficiencies. J Leukoc Biol. 2009;85:335–43. Scholar
  75. 75.
    Anderson DC, et al. The severe and moderate phenotypes of heritable Mac-1, LFA-1 deficiency: their quantitative definition and relation to leukocyte dysfunction and clinical features. J Infect Dis. 1985;152:668–89.CrossRefPubMedGoogle Scholar
  76. 76.
    Kuijpers TW, et al. Leukocyte adhesion deficiency type 1 (LAD-1)/variant. A novel immunodeficiency syndrome characterized by dysfunctional beta2 integrins. J Clin Invest. 1997;100:1725–33. Scholar
  77. 77.
    Hogg N, et al. A novel leukocyte adhesion deficiency caused by expressed but nonfunctional beta2 integrins Mac-1 and LFA-1. J Clin Invest. 1999;103:97–106. Scholar
  78. 78.
    Thomas C, et al. Results of allogeneic bone marrow transplantation in patients with leukocyte adhesion deficiency. Blood. 1995;86:1629–35.PubMedGoogle Scholar
  79. 79.
    Qasim W, et al. Allogeneic hematopoietic stem-cell transplantation for leukocyte adhesion deficiency. Pediatrics. 2009;123:836–40. Scholar
  80. 80.
    Uzel G, et al. Reversion mutations in patients with leukocyte adhesion deficiency type-1 (LAD-1). Blood. 2008;111:209–18. Scholar
  81. 81.
    Lubke T, et al. Complementation cloning identifies CDG-IIc, a new type of congenital disorders of glycosylation, as a GDP-fucose transporter deficiency. Nat Genet. 2001;28:73–6. Scholar
  82. 82.
    Luhn K, Wild MK, Eckhardt M, Gerardy-Schahn R, Vestweber D. The gene defective in leukocyte adhesion deficiency II encodes a putative GDP-fucose transporter. Nat Genet. 2001;28:69–72. Scholar
  83. 83.
    Gazit Y, et al. Leukocyte adhesion deficiency type II: long-term follow-up and review of the literature. J Clin Immunol. 2010;30:308–13. Scholar
  84. 84.
    Etzioni A, Gershoni-Baruch R, Pollack S, Shehadeh N. Leukocyte adhesion deficiency type II: long-term follow-up. J Allergy Clin Immunol. 1998;102:323–4.CrossRefPubMedGoogle Scholar
  85. 85.
    Marquardt T, et al. Correction of leukocyte adhesion deficiency type II with oral fucose. Blood. 1999;94:3976–85.PubMedGoogle Scholar
  86. 86.
    Etzioni A, Tonetti M. Fucose supplementation in leukocyte adhesion deficiency type II. Blood. 2000;95:3641–3.PubMedGoogle Scholar
  87. 87.
    Mory A, et al. Kindlin-3: a new gene involved in the pathogenesis of LAD-III. Blood. 2008;112:2591. Scholar
  88. 88.
    Kuijpers TW, et al. LAD-1/variant syndrome is caused by mutations in FERMT3. Blood. 2009;113:4740–6. Scholar
  89. 89.
    Stepensky PY, et al. Leukocyte adhesion deficiency type III: clinical features and treatment with stem cell transplantation. J Pediatr Hematol Oncol. 2015;37:264–8. Scholar
  90. 90.
    Ambruso DR, et al. Human neutrophil immunodeficiency syndrome is associated with an inhibitory Rac2 mutation. Proc Natl Acad Sci U S A. 2000;97:4654–9. Scholar
  91. 91.
    Williams DA, et al. Dominant negative mutation of the hematopoietic-specific Rho GTPase, Rac2, is associated with a human phagocyte immunodeficiency. Blood. 2000;96:1646–54.PubMedGoogle Scholar
  92. 92.
    Routes JM, et al. Statewide newborn screening for severe T-cell lymphopenia. JAMA. 2009;302:2465–70. Scholar
  93. 93.
    Accetta D, et al. Human phagocyte defect caused by a Rac2 mutation detected by means of neonatal screening for T-cell lymphopenia. J Allergy Clin Immunol. 2011;127:535–538.e531-532. Scholar
  94. 94.
    Alkhairy OK, et al. RAC2 loss-of-function mutation in 2 siblings with characteristics of common variable immunodeficiency. J Allergy Clin Immunol. 2015;135:1380–1384.e1381-1385. Scholar
  95. 95.
    Grimbacher B, et al. Hyper-IgE syndrome with recurrent infections – an autosomal dominant multisystem disorder. N Engl J Med. 1999;340:692–702. Scholar
  96. 96.
    Minegishi Y, et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature. 2007;448:1058–62. Scholar
  97. 97.
    Holland SM, et al. STAT3 mutations in the hyper-IgE syndrome. N Engl J Med. 2007;357:1608–19. Scholar
  98. 98.
    Minegishi Y, et al. Molecular explanation for the contradiction between systemic Th17 defect and localized bacterial infection in hyper-IgE syndrome. J Exp Med. 2009;206:1291–301. Scholar
  99. 99.
    Freeman AF, et al. Lung parenchyma surgery in autosomal dominant hyper-IgE syndrome. J Clin Immunol. 2013;33:896–902. Scholar
  100. 100.
    Freeman AF, Holland SM. The hyper-IgE syndromes. Immunol Allergy Clin N Am. 2008;28:277–91., viii. Scholar
  101. 101.
    Ling JC, et al. Coronary artery aneurysms in patients with hyper IgE recurrent infection syndrome. Clin Immunol (Orlando, Fla). 2007;122:255–8. Scholar
  102. 102.
    Freeman AF, et al. Brain abnormalities in patients with hyperimmunoglobulin E syndrome. Pediatrics. 2007;119:e1121–5. Scholar
  103. 103.
    Engelhardt KR, et al. The extended clinical phenotype of 64 patients with DOCK8 deficiency. J Allergy Clin Immunol. 2015;136:402–12. Scholar
  104. 104.
    Zhang Q, et al. Combined immunodeficiency associated with DOCK8 mutations. N Engl J Med. 2009;361:2046–55. Scholar
  105. 105.
    Engelhardt KR, et al. Large deletions and point mutations involving the dedicator of cytokinesis 8 (DOCK8) in the autosomal-recessive form of hyper-IgE syndrome. J Allergy Clin Immunol. 2009;124:1289–1302.e1284. Scholar
  106. 106.
    Sassi A, et al. Hypomorphic, homozygous mutations in phosphoglucomutase 3 impair immunity and increase serum IgE levels. J Allergy Clin Immunol. 2014;133:1410–142013. Scholar
  107. 107.
    Zhang Y, et al. Autosomal recessive PGM3 mutations link glycosylation defects to atopy, immune deficiency, autoimmunity, and neurocognitive impairment. J Allergy Clin Immunol. 2014;133:1400–1409.e1405. Scholar
  108. 108.
    Minegishi Y, et al. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity. 2006;25:745–55. Scholar
  109. 109.
    Kreins AY, et al. Human TYK2 deficiency: mycobacterial and viral infections without hyper-IgE syndrome. J Exp Med. 2015;212:1641–62. Scholar
  110. 110.
    Bogunovic D, et al. Mycobacterial disease and impaired IFN-gamma immunity in humans with inherited ISG15 deficiency. Science. 2012;337:1684–8. Scholar
  111. 111.
    Hambleton S, et al. IRF8 mutations and human dendritic-cell immunodeficiency. N Engl J Med. 2011;365:127–38. Scholar
  112. 112.
    Haverkamp MH, van Dissel JT, Holland SM. Human host genetic factors in nontuberculous mycobacterial infection: lessons from single gene disorders affecting innate and adaptive immunity and lessons from molecular defects in interferon-gamma-dependent signaling. Microbes Infect. 2006;8:1157–66. Scholar
  113. 113.
    Al-Muhsen S, Casanova JL. The genetic heterogeneity of mendelian susceptibility to mycobacterial diseases. J Allergy Clin Immunol. 2008;122:1043–51.; quiz 1052–1043. Scholar
  114. 114.
    de Vor IC, et al. Deletion of the entire interferon-gamma receptor 1 gene causing complete deficiency in three related patients. J Clin Immunol. 2016;36:195–203. Scholar
  115. 115.
    Prando C, et al. Inherited IL-12p40 deficiency: genetic, immunologic, and clinical features of 49 patients from 30 kindreds. Medicine (Baltimore). 2013;92:109–22. Scholar
  116. 116.
    Martinez-Barricarte R, et al. Mycobacterium simiae infection in two unrelated patients with different forms of inherited IFN-gammaR2 deficiency. J Clin Immunol. 2014;34:904–9. Scholar
  117. 117.
    Wu UI, Holland SM. Host susceptibility to non-tuberculous mycobacterial infections. Lancet Infect Dis. 2015;15:968–80. Scholar
  118. 118.
    Spinner MA, et al. GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. Blood. 2014;123:809–21. Scholar
  119. 119.
    Grabbe C, Husnjak K, Dikic I. The spatial and temporal organization of ubiquitin networks. Nat Rev Mol Cell Biol. 2011;12:295–307. Scholar
  120. 120.
    Smahi A, et al. Genomic rearrangement in NEMO impairs NF-kappaB activation and is a cause of incontinentia pigmenti. Int Incontinentia Pigmenti (IP) Consortium Nat. 2000;405:466–72.Google Scholar
  121. 121.
    Filipe-Santos O, et al. X-linked susceptibility to mycobacteria is caused by mutations in NEMO impairing CD40-dependent IL-12 production. J Exp Med. 2006;203:1745–59. Scholar
  122. 122.
    Orange JS, et al. The presentation and natural history of immunodeficiency caused by nuclear factor kappaB essential modulator mutation. J Allergy Clin Immunol. 2004;113:725–33. Scholar
  123. 123.
    Ferwerda B, et al. Human dectin-1 deficiency and mucocutaneous fungal infections. N Engl J Med. 2009;361:1760–7. Scholar
  124. 124.
    Glocker EO, et al. A homozygous CARD9 mutation in a family with susceptibility to fungal infections. N Engl J Med. 2009;361:1727–35. Scholar
  125. 125.
    Toubiana J, Okada S, Hiller J, et al. Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype. Blood. 2016;127(25):3154–64.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Laboratory of Clinical Infectious DiseasesNational Institute of Allergy and Infectious Diseases, NIHBethesdaUSA

Personalised recommendations